HCC1806細(xì)胞

細(xì)胞形態(tài)： 上皮樣

運(yùn)輸方式： 凍存運(yùn)輸

生長(zhǎng)狀態(tài)： 貼壁生長(zhǎng)

數(shù)量： 大量

是否是腫瘤細(xì)胞： 1

物種來源： 人

年限： TNM stage IIB, grade 2

ATCC Number： CRL-2335?

器官來源： **

相關(guān)**： 其他**

Designations: HCC1806

Depositors: AF Gazdar, AK Virmani

HCC1806細(xì)胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent, The line grows as attached medium-sized epithelial cells without floating cells.

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: mammary gland; breast

Tumor Stage: TNM stage IIB, grade 2

Disease: primary acantholytic squamous cell carcinoma

Cellular Products: Epithelial glycoprotein 2 [EGP2]; cytokeratin 19

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. HCC1806細(xì)胞Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.

Applications: The cells are poorly differentiated.

HCC1806 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.

The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR).

The cells are negative for expression of Her2-neu and for expression of p53.

Receptors: estrogen receptor, negative

progesterone receptor, negative

Oncogene: her2/neu -, p53 -

Cytogenetic Analysis: Number of cells examined = 59; Modal Chromosome Number = 75 with a range of 65 to 79; Polyploidy Rate = 22%

Age: 60 years

Gender: female

Ethnicity: Black

Comments: HCC1806細(xì)胞The HCC1806 cell line was initiated on July 31, 1995, and took 10 months to establish.

The tumor was classified as a TNM Stage IIB, grade 2, acantholytic squamous carcinoma with no lymph node metastasis.

There was no family history of breast cancer.

The cells are poorly differentiated.

The cells are negative for expression of Her2-neu and for expression of p53.

HCC1806 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.

The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR).

The cells are homozygous for deletions in the FHIT gene at 3p14.2.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended

Medium Renewal: Every 2 to 3 days

Remove medium, rinse with 0.25% trypsin, 0.03% EDTA solution, add an additional 1 to 2 ml of trypsin solution and allow the flask to set at room temperature (or incubate at 37C) until cells detach.

Add fresh culture medium, aspirate and dispense into new culture flasks.

Preservation: Culture medium, 95%; DMSO, 5%

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 32258: HCC1806細(xì)胞Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768

38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771